Takeda Entities Exit HilleVax Stake: 6.724M Shares Tendered at $1.95
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. reported disposal of all their HilleVax, Inc. (HLVX) common stock held through Takeda Vaccines. On 09/17/2025, 6,724,000 shares were sold pursuant to a cash tender offer by XOMA Royalty Corporation and XRA 4 Corp. at a price of $1.95 per share, with closing announced on 09/17/2025.
The filing states that following the transaction the reporting persons hold 0 shares beneficially. The shares were held directly by Takeda Vaccines, Inc., an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and the filing explains the ownership chain among Takeda entities.
Positive
- Completed sale via formal tender offer with disclosed price of $1.95 per share, providing clear transaction terms
- Filing discloses ownership chain showing securities held directly by Takeda Vaccines, Inc. and the parent company structure
Negative
- Reporting persons reduced beneficial ownership to 0, disposing 6,724,000 shares which removes a prior director/10% owner's stake
- Large block disposition may materially change HLVX's shareholder composition and insider ownership alignment
Insights
TL;DR: Major shareholder sold entire stake via tender offer, eliminating beneficial ownership—significant corporate governance event.
The Form 4 records a disposal of 6,724,000 HLVX shares at $1.95 per share on 09/17/2025, resulting in reported beneficial ownership of zero. From a governance perspective, a director/10% owner exiting fully through a third-party tender offer is material: it removes a sizable strategic shareholder and could affect board alignment and monitoring. The filing also clearly documents the ownership chain, attributing holdings to Takeda Vaccines, Inc. and ultimately Takeda Pharmaceutical Company Limited.
TL;DR: Large block sale executed at disclosed tender price; transaction is material to HLVX float and ownership profile.
The transaction disposed of 6,724,000 common shares at $1.95 per share via a completed tender offer announced 09/17/2025. The reporting persons are a director and identified as 10% owners prior to the sale; post-transaction beneficial ownership is reported as zero. This change materially alters the company’s shareholder base and reduces insider ownership concentration as disclosed in the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| U | Common Stock | 6,724,000 | $1.95 | $13.11M |
Footnotes (1)
- These shares were sold pursuant to the cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of common stock of the Issuer at an offer price of (i) $1.95 per share of common stock and (ii) one non-transferable contractual contingent value right. The Tender Offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced on September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 17, 2025, Parent irrevocably accepted for payment all shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such shares in accordance with the Tender Offer. Takeda Pharmaceutical Company Limited has beneficial ownership of the reported securities, all of which are held directly by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
